You are here: Industry Insights > immunotherapy

News List

The Landscape of Biomarkers: From Traditional Measures to Multi-Omics Powerhouses Shruti Talshi
February 18, 2024
A biomarker is an indicator that can be quantified to show whether a biological process is pathogenic, normal, or responding to an intervention or exposure.
Breakthroughs in Melanoma Immunotherapy & RNA Vaccines Daivd Orchard Webb/PharmaSources
July 03, 2023
Melanoma is a type of skin cancer that develops from pigment-producing cells called melanocytes.
A Glimpse of the Oncology Drug Treatment Market in China PharmaSources/Xiaoyaowan
May 31, 2021
According to statistics, the market size of China’s oncology treatment industry reached RMB387.6 billion in 2020, with a compound annual growth rate of 10.3% in the past five years as compared to RMB261.4 billion in 2016, and this market size is expected
Malaysian Genomics Pivots to Biopharmaceuticals for Growth PharmaSources
March 07, 2023
Group reports lower revenue for 2Q on switch to immunotherapy and cell therapies from vaccines
Antihistamines can influence immunotherapy response by enhancing T cell activation FirstWordPharma
November 29, 2021
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication, was associated with improved responses to immune checkpoint inhibitors.
Creative Medical Technology Holdings Announces $3.8 Million Private Placement with Institutional Investors firstwordpharma
August 10, 2021
Creative Medical Technology Holdings, Inc. ("CELZ," the "Company", "we", "our" or "us") (OTC: CELZ) today announced that it has entered into definitive agreements with accredited institutional investors for gross proceeds of approximately $3,788,000.
New breakthrough to help immune systems in the fight against cancer prnewswire
July 28, 2021
New research has identified potential treatment that could improve the human immune system's ability to search out and destroy cancer cells within the body.
Aristea Completes $63 Million Series B Financing to Accelerate Clinical Development of Novel Immunotherapy Drugs for the Treatment of Orphan Diseases firstwordpharma
July 28, 2021
Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory orphan diseases, today announced the closing of a $63 million Series B financing.
OncoSec Appoints Brian Leuthner as Interim CEO firstwordpharma
June 25, 2021
OncoSec Medical Incorporated (NASDAQ:ONCS) today announced that Daniel O'Connor has resigned and that Brian Leuthner, formerly Chief Operating Officer, has been appointed Interim Chief Executive Officer, effective June 25, 2021.
Werewolf Therapeutics Appoints Mike Sherman to its Board of Directors firstwordpharma
May 31, 2021
Werewolf Therapeutics, Inc. today announced the appointment of Mike Sherman, chief executive officer of Chimerix, Inc., as a member of its board of directors.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page